DAA治疗获SVR后HCV患者胞外囊泡仍携带促纤维化信号
研究对比15例健康供者与16例HCV感染患者DAA治疗前后血浆胞外囊泡(EVs),发现抗纤维化miRNA在治疗前显著低表达,治疗后部分仍低;蛋白组学显示促纤维化蛋白DIAPH1在治疗前后均上调(Log2 fold change 4.4)。提示DAA获SVR后EVs结构改变可能促进肝病进展。
要点
- DAA获SVR后HCV患者EVs仍存在促纤维化miRNA低表达和DIAPH1上调。
- 抗纤维化miR204-5p和miR143-3p在治疗后仍显著低于健康供者。
- EVs改变可能作为肝病进展生物标志物或治疗靶点。
核心结论
- DAA治疗获SVR后HCV患者血浆EVs存在结构改变,可能促进长期肝病进展。
研究设计与样本
- 功能与miRNA分析纳入15例健康供者和16例HCV患者DAA治疗前(T0)及治疗后(T6)血浆EVs。
- 蛋白组学和western blot分析纳入17例健康供者和23例HCV患者(T0和T6)血浆EVs。
- LX2细胞功能分析检测EVs对纤维化标志物mRNA和蛋白的调控。
主要发现
- T0 EVs中miR204-5p、miR181a-5p、miR143-3p、miR93-5p和miR122-5p较健康供者EVs显著低表达(p<0.05)。
- T6 EVs中miR204-5p和miR143-3p较健康供者EVs显著低表达(p<0.05)。
- 蛋白组学显示T0和T6 EVs中多种蛋白相对健康供者发生调控,促纤维化蛋白DIAPH1上调(Log2 fold change 4.4)。
临床怎么用
- 对DAA获SVR的HCV患者,尤其纤维化或肝硬化者,仍需监测肝病进展。
- EVs中miRNA和DIAPH1等蛋白改变有望作为生物标志物或治疗靶点。
局限性
- 样本量较小(功能分析15例健康供者、16例患者;蛋白组学17例健康供者、23例患者)。
- 未报告长期临床结局,EVs改变与肝病进展的因果关系需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with HCV who achieve a sustained virological response (SVR) on direct-acting antiviral (DAA) therapy still need to be monitored for signs of liver disease progression. To this end, the identification of both disease biomarkers and therapeutic targets is necessary. METHODS: Extracellular vesicles (EVs) purified from plasma of 15 healthy donors (HDs), and 16 HCV-infected patients before (T0) and after (T6) DAA treatment were utilized for functional and miRNA cargo analysis. EVs purified from plasma of 17 HDs and 23 HCV-infected patients (T0 and T6) were employed for proteomic and western blot analyses. Functional analysis in LX2 cells measured fibrotic markers (mRNAs and proteins) in response to EVs. Structural analysis was performed by qPCR, label-free liquid chromatography-mass spectrometry and western blot. RESULTS: On the basis of observations indicating functional differences (i.e. modulation of FN-1, ACTA2, Smad2/3 phosphorylation, collagen deposition) of plasma-derived EVs from HDs, T0 and T6, we performed structural analysis of EVs. We found consistent differences in terms of both miRNA and protein cargos: (i) antifibrogenic miR204-5p, miR181a-5p, miR143-3p, miR93-5p and miR122-5p were statistically underrepresented in T0 EVs compared to HD EVs, while miR204-5p and miR143-3p were statistically underrepresented in T6 EVs compared to HD EVs (p <0.05); (ii) proteomic analysis highlighted, in both T0 and T6, the modulation of several proteins with respect to HDs; among them, the fibrogenic protein DIAPH1 was upregulated (Log2 fold change of 4.4). CONCLUSIONS: Taken together, these results highlight structural EV modifications that are conceivably causal for long-term liver disease progression in patients with HCV despite DAA-mediated SVR. LAY SUMMARY: Direct-acting antivirals lead to virological cure in the majority of patients with chronic hepatitis C virus infection. However, the risk of liver disease progression or complications in patients with fibrosis and cirrhosis remains in some patients even after virological cure. Herein, we show that extracellular vesicle modifications could be linked to long-term liver disease progression in patients who have achieved virological cure; these modifications could potentially be used as biomarkers or treatment targets in such patients.
引用
- Montaldo C, Terri M, Riccioni V, et al. Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response. J Hepatol. 2021. PMID: 34271004. doi:10.1016/j.jhep.2021.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。